Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment

BMC Gastroenterology

Volumn 10, Issue , 2010, Pages

  Ogawa, Eiichi ^a   Furusyo, Norihiro ^a,b   Toyoda, Kazuhiro ^a   Taniai, Hiroaki ^a   Otaguro, Shigeru ^a   Kainuma, Mosaburo ^a   Murata, Masayuki ^a   Sawayama, Yasunori ^a   Hayashi, Jun ^a,b  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2B;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PREDICTION; QUALITATIVE ANALYSIS; RETROSPECTIVE STUDY; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; BIOPSY; COMPARATIVE STUDY; DRUG COMBINATION; FOLLOW UP; GENETICS; LIVER; LIVER FUNCTION TEST; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOGENICITY; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; VIROLOGY; VIRULENCE;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; BIOPSY; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRULENCE;

EID: 77950833163     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-10-38     Document Type: Article

References (25)

1. Hayashi J, Kishihara Y, Yamaji K, Furusyo N, Yamamoto T, Pae Y, Etoh Y, Ikematsu H, Kashiwagi S. Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection. Hepatology 1997, 25:697-701. 10.1002/hep.510250334, 9049221.
2. Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004, 53:744-9. 10.1136/gut.2003.020263, 1774055, 15082595.
3. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK, . Hepatitis Interventional Therapy Group A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001, 34:395-403. 10.1053/jhep.2001.26371, 11481625, Hepatitis Interventional Therapy Group.
4. Chander G, Sulkowski MS, Jenckes MW, Torbenson MS, Herlong HF, Bass EB, Gebo KA. Treatment of chronic hepatitis C: a systematic review. Hepatology 2002, 36:S135-44. 10.1002/hep.1840360718, 12407587.
5. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339:1485-92. 10.1056/NEJM199811193392101, 9819446.
6. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998, 352:1426-32. 10.1016/S0140-6736(98)07124-4, 9807989.
7. Furusyo N, Murata M, Hayashi J. Interferon treatment of hepatitis C virus infection: From basic biology to clinical application. Hepatitis C virus disease: Immunology and Clinical Applications 2008, 148-67. New York: Springer Science + Business Media, LLC, Jirillo E.
8. Hayashi J, Kishihara Y, Ueno K, Yamaji K, Kawakami Y, Furusyo N, Sawayama Y, Kashiwagi S. Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Arch Intern Med 1998, 158:177-81. 10.1001/archinte.158.2.177, 9448556.
9. Furusyo N, Katoh M, Tanabe Y, Kajiwara E, Maruyama T, Shimono J, Sakai H, Nakamuta M, Nomura H, Matsumoto A, Shimoda S, Takahashi K, Azuma K, Hayashi J, . Kyusyu University Liver Disease Study Group Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: a project of the Kyushu University Liver Disease Study Group. World J Gastoroenterol 2006, 12:784-90. Kyusyu University Liver Disease Study Group.
10. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003, 38:645-52. 10.1053/jhep.2003.50364, 12939591.
11. Lee SS, Heathcote EJ, Reddy KR, Zeuzem S, Fried MW, Wright TL, Pockros PJ, Häussinger D, Smith CI, Lin A, Pappas SC. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol 2002, 37:500-6. 10.1016/S0168-8278(02)00211-8, 12217604.
12. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxì A, Chaneac M, Reddy KR. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005, 43:425-33. 10.1016/j.jhep.2005.04.009, 15990196.
13. Gerken G, Rothaar T, Rumi MG, Soffredini R, Trippler M, Blunk MJ, Butcher A, Soviero S, Colucci G. Performance of the COBAS AMPLICOR HCV MONITOR test, version 2.0, an automated reverse transcription-PCR quantitative system for hepatitis C virus load determination. J Clin Microbiol 2000, 38:2210-4. 86766, 10834978.
14. Sandres-Sauné K, Abravanel F, Nicot F, Peron JM, Alric L, Boineau J, Pasquier C, Izopet J. Detection and quantitation of HCV RNA using real-time PCR after automated sample processing. J Med Virol 2007, 79:1821-6. 10.1002/jmv.21003, 17935166.
15. Sizmann D, Boeck C, Boelter J, Fischer D, Miethke M, Nicolaus S, Zadak M, Babiel R. Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan system. J Clin Virol 2007, 38:326-33. 10.1016/j.jcv.2006.12.021, 17344093.
16. Furusyo N, Kajiwara E, Takahashi K, Momura H, Tanabe Y, Masumoto A, Maruyama T, Nakamuta M, Enjoji M, Azuma K, Shimono J, Sakai H, Shimoda S, Hayashi J, . Kyushu University Liver Disease Study (KULDS) Group Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: Project of the Kyushu University Liver Disease Study Group. J Gastroenterol Hepatol 2008, 23:1094-104. 10.1111/j.1440-1746.2008.05319.x, 18248381, Kyushu University Liver Disease Study (KULDS) Group.
17. Lee SC, Antony A, Lee N, Leibow J, Yang JQ, Soviero S, Gutekunst K, Rosenstraus M. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol 2000, 38:4171-9. 87559, 11060086.
18. Ogawa E, Furusyo N, Toyoda K, Takeoka H, Otaguro S, Hamada M, Murata M, Sawayama Y, Hayashi J. Transient elastography for patients with chronic hepatitis B and C virus infection: Non-invasive, quantitative assessment of liver fibrosis. Hepatol Res 2007, 37:1002-10. 10.1111/j.1872-034X.2007.00160.x, 17608672.
19. Simmonds P, Holmes SC, Cha TA, Chan SW, McOmish S, Irvine B, Beall E, Yap PL, Kolberg J, Urdea MS. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993, 74:2391-9. 10.1099/0022-1317-74-11-2391, 8245854.
20. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282:103-7. 10.1126/science.282.5386.103, 9756471.
21. Strader DB, Wright T, Thomas DL, Seeff LB. American Association for the Study of Liver Disease. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 39:1147-71. 10.1002/hep.20119, 15057920.
22. Alberti A, Benvegnu L. Management of hepatitis C. J Hepatol 2003, 36:S104-18.
23. Hayashi J, Kawakami Y, Nabeshima A, Kishihara Y, Furusyo N, Sawayama Y, Kinukawa N, Kashiwagi S. Comparison of HCV RNA levels by branched DNA probe assay and by competitive polymerase chain reaction to predict effectiveness of interferon treatment for patients with chronic hepatitis C virus. Dig Dis Sci 1998, 43:384-91. 10.1023/A:1018874910195, 9512135.
24. Furusyo N, Hayashi J, Kashiwagi K, Nakashima H, Nabeshima S, Sawayama Y, Kinukawa N, Kashiwagi S. Hepatitis C virus (HCV) RNA level determined by second-generation branched-DNA probe assay as predictor of response to interferon treatment in patients with chronic HCV viremia. Dig Dis Sci 2002, 47:535-42. 10.1023/A:1017955700585, 11911338.
25. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, Buggisch P, Goeser T, Rasenack J, Pape GR, Schmidt WE, Kallinowski B, Klinker H, Spengler U, Martus P, Alshuth U, Zeuzem S. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006, 130:1086-97. 10.1053/j.gastro.2006.02.015, 16618403.